{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:18:56Z","timestamp":1767658736861,"version":"3.48.0"},"reference-count":125,"publisher":"Georg Thieme Verlag KG","issue":"05","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Respir Crit Care Med"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Drug-induced pneumonitis is a significant and potentially life-threatening complication associated with multiple lung cancer therapies. As novel therapies are introduced and incorporated into updated treatment algorithms, it is crucial to anticipate, recognize, and manage these events readily and comprehensively. As experience with these agents accumulates in real-world settings, so too does our appreciation for patient risk factors, the need for personalized monitoring strategies, the heterogeneity of both clinical and radiographic presentations, and the persistent importance of a systematic approach to diagnosis and management. Novel therapies are responsible for significant improvements in lung cancer survival, but enthusiasm for this progress must be tempered by mitigation and management of inherent risks to avoid undue morbidity and mortality for our patients. Challenging clinical scenarios such as steroid-refractory pneumonitis highlight the importance of thorough evaluation, confident attribution, and aggressive early management. Future elucidation of the pathophysiology of these reactions will hopefully refine future diagnostic and therapeutic options. A collaborative, multidisciplinary approach is essential to optimize patient safety and outcomes in lung cancer care. In this study, we describe approaches to pretreatment assessment, evaluation of suspected pneumonitis, and management of pneumonitis on a drug-specific basis. We emphasize emerging data and drug classes, while also highlighting remaining areas of uncertainty.<\/jats:p>","DOI":"10.1055\/a-2666-7519","type":"journal-article","created":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T22:44:35Z","timestamp":1753742675000},"page":"452-466","source":"Crossref","is-referenced-by-count":0,"title":["Update on Drug-Induced Pneumonitis in Lung Cancer"],"prefix":"10.1055","volume":"46","author":[{"given":"Kathleen A.","family":"McAvoy","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine\/Section of Pulmonary, Critical Care, and Sleep Medicine, Yale University School of Medicine, New Haven, Connecticut"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer D.","family":"Possick","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine\/Section of Pulmonary, Critical Care, and Sleep Medicine, Yale University School of Medicine, New Haven, Connecticut"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2025,8,29]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1266850","DOI":"10.3389\/fimmu.2024.1266850","article-title":"Immune checkpoint inhibitor-related pneumonitis: research advances in prediction and management","volume":"15","author":"M X Lin","year":"2024","journal-title":"Front Immunol"},{"issue":"04","key":"ref2","doi-asserted-by":"crossref","first-page":"100554","DOI":"10.1016\/j.esmoop.2022.100554","article-title":"Pooled analysis of drug-related interstitial lung disease and\/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies","volume":"7","author":"C A Powell","year":"2022","journal-title":"ESMO Open"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2152\/jmi.71.9","article-title":"Current pharmacotherapies for advanced lung cancer with pre-existing interstitial lung disease : a literature review and future perspectives","volume":"71","author":"M Hanibuchi","year":"2024","journal-title":"J Med Invest"},{"issue":"03","key":"ref4","first-page":"1103","article-title":"Interstitial lung disease associated with docetaxel in patients with advanced non-small cell lung cancer","volume":"32","author":"A Tamiya","year":"2012","journal-title":"Anticancer Res"},{"issue":"04","key":"ref5","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1093\/jjco\/hyx010","article-title":"Pemetrexed-related interstitial lung disease reported from post marketing surveillance (malignant pleural mesothelioma\/non-small cell lung cancer)","volume":"47","author":"K Tomii","year":"2017","journal-title":"Jpn J Clin Oncol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.lungcan.2018.06.032","article-title":"Pneumonitis in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitor: meta-analysis of 153 cohorts with 15,713 patients: meta-analysis of incidence and risk factors of EGFR-TKI pneumonitis in NSCLC","volume":"123","author":"C H Suh","year":"2018","journal-title":"Lung Cancer"},{"issue":"04","key":"ref7","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.jtho.2018.11.022","article-title":"Interstitial lung disease onset and its risk factors in Japanese patients with ALK-positive NSCLC after treatment with crizotinib","volume":"14","author":"A Gemma","year":"2019","journal-title":"J Thorac Oncol"},{"issue":"01","key":"ref8","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0169-5002(02)00532-9","article-title":"Concurrent two-dimensional radiotherapy and weekly docetaxel in the treatment of stage III non-small cell lung cancer: a good local response but no good survival due to radiation pneumonitis","volume":"40","author":"H Onishi","year":"2003","journal-title":"Lung Cancer"},{"issue":"01","key":"ref9","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1046\/j.0767-3981.2003.00206.x","article-title":"Gemcitabine-induced severe pulmonary toxicity","volume":"18","author":"F Barl\u00e9si","year":"2004","journal-title":"Fundam Clin Pharmacol"},{"issue":"12","key":"ref10","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1016\/j.jtho.2018.08.2035","article-title":"Pneumonitis in non-small cell lung cancer patients receiving immune checkpoint immunotherapy: incidence and risk factors","volume":"13","author":"K Suresh","year":"2018","journal-title":"J Thorac Oncol"},{"issue":"07","key":"ref11","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJMoa2402614","article-title":"Osimertinib after chemoradiotherapy in stage III EGFR-mutated NSCLC","volume":"391","author":"S Lu","year":"2024","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"103960","DOI":"10.1016\/j.critrevonc.2023.103960","article-title":"Incidence of antibody-drug conjugates-related pneumonitis in patients with solid tumors: a systematic review and meta-analysis","volume":"184","author":"Z Zhu","year":"2023","journal-title":"Crit Rev Oncol Hematol"},{"issue":"08","key":"ref13","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1001\/jamaoncol.2017.4526","article-title":"EGFR-TKI-associated interstitial pneumonitis in nivolumab-treated patients with non-small cell lung cancer","volume":"4","author":"Y Oshima","year":"2018","journal-title":"JAMA Oncol"},{"issue":"05","key":"ref14","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1093\/annonc\/mdz077","article-title":"Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib","volume":"30","author":"A J Schoenfeld","year":"2019","journal-title":"Ann Oncol"},{"issue":"04","key":"ref15","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.resinv.2018.03.002","article-title":"Anticancer drug treatment for advanced lung cancer with interstitial lung disease","volume":"56","author":"K Otsubo","year":"2018","journal-title":"Respir Investig"},{"issue":"02","key":"ref16","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.path.2023.11.007","article-title":"Interstitial lung abnormalities","volume":"17","author":"M B Beasley","year":"2024","journal-title":"Surg Pathol Clin"},{"issue":"16","key":"ref17","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.3390\/cancers16162837","article-title":"Lung cancer and interstitial lung diseases","volume":"16","author":"F Drakopanagiotakis","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"20","key":"ref18","doi-asserted-by":"crossref","first-page":"3743","DOI":"10.1002\/cam4.4750","article-title":"Impact of pre-existing interstitial lung abnormal shadow on lung injury development and severity in patients of non-small cell lung cancer treated with osimertinib","volume":"11","author":"R Shibaki","year":"2022","journal-title":"Cancer Med"},{"issue":"03","key":"ref19","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/1759-7714.13725","article-title":"Pre-existing interstitial lung disease does not affect prognosis in non-small cell lung cancer patients with PD-L1 expression \u226550% on first-line pembrolizumab","volume":"12","author":"O Yamaguchi","year":"2021","journal-title":"Thorac Cancer"},{"issue":"06","key":"ref20","doi-asserted-by":"crossref","first-page":"2200380","DOI":"10.1183\/13993003.00380-2022","article-title":"Nintedanib plus chemotherapy for nonsmall cell lung cancer with idiopathic pulmonary fibrosis: a randomised phase 3 trial","volume":"60","author":"K Otsubo","year":"2022","journal-title":"Eur Respir J"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.lungcan.2020.08.015","article-title":"Association of baseline peripheral-blood eosinophil count with immune checkpoint inhibitor-related pneumonitis and clinical outcomes in patients with non-small cell lung cancer receiving immune checkpoint inhibitors","volume":"150","author":"X Chu","year":"2020","journal-title":"Lung Cancer"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"840313","DOI":"10.3389\/fimmu.2022.840313","article-title":"Interleukin-10 is a promising marker for immune-related adverse events in patients with non-small cell lung cancer receiving immunotherapy","volume":"13","author":"H Wang","year":"2022","journal-title":"Front Immunol"},{"issue":"04","key":"ref23","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/resp.14425","article-title":"Predictive value of serum high-mobility group box 1 levels for checkpoint inhibitor pneumonitis","volume":"28","author":"H Tanahashi","year":"2023","journal-title":"Respirology"},{"issue":"09","key":"ref24","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.3390\/cells9091964","article-title":"HLA expression correlates to the risk of immune checkpoint inhibitor-induced pneumonitis","volume":"9","author":"P Correale","year":"2020","journal-title":"Cells"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ejca.2023.01.034","article-title":"Immunogenetic variations predict immune-related adverse events for PD-1\/PD-L1 inhibitors","volume":"184","author":"Z Xin","year":"2023","journal-title":"Eur J Cancer"},{"issue":"03","key":"ref26","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/j.acra.2024.09.053","article-title":"Radiomics biomarkers to predict checkpoint inhibitor pneumonitis in non-small cell lung cancer","volume":"32","author":"Y Du","year":"2025","journal-title":"Acad Radiol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"1251645","DOI":"10.3389\/fimmu.2023.1251645","article-title":"Clinical applications of radiomics in non-small cell lung cancer patients with immune checkpoint inhibitor-related pneumonitis","volume":"14","author":"Y Shu","year":"2023","journal-title":"Front Immunol"},{"issue":"04","key":"ref28","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1164\/rccm.201307-1269ST","article-title":"An official American Thoracic Society\/European Respiratory Society statement: the role of the pulmonologist in the diagnosis and management of lung cancer","volume":"188","author":"M Gaga","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"issue":"09","key":"ref30","doi-asserted-by":"crossref","first-page":"8019","DOI":"10.3390\/curroncol30090582","article-title":"Managing the risk of lung toxicity with trastuzumab deruxtecan (T-DXd): a Canadian perspective","volume":"30","author":"J W Henning","year":"2023","journal-title":"Curr Oncol"},{"issue":"01","key":"ref31","doi-asserted-by":"crossref","first-page":"e001490","DOI":"10.1136\/bmjresp-2022-001490","article-title":"Diagnoses and treatments for participants with interstitial lung abnormalities detected in the Yorkshire lung screening trial","volume":"10","author":"S Upperton","year":"2023","journal-title":"BMJ Open Respir Res"},{"issue":"01","key":"ref32","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s00262-017-2071-2","article-title":"Ipilimumab and early signs of pulmonary toxicity in patients with metastastic melanoma: a prospective observational study","volume":"67","author":"D Franzen","year":"2018","journal-title":"Cancer Immunol Immunother"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"102378","DOI":"10.1016\/j.ctrv.2022.102378","article-title":"Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)-related interstitial lung disease\/pneumonitis-Focus on proactive monitoring, diagnosis, and management","volume":"106","author":"S M Swain","year":"2022","journal-title":"Cancer Treat Rev"},{"issue":"S 02","key":"ref34","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1038\/sj.bjc.6602064","article-title":"Diagnosis and management of drug-associated interstitial lung disease","volume":"91","author":"N L M\u00fcller","year":"2004","journal-title":"Br J Cancer"},{"key":"ref35","volume-title":"Drug-Induced Pulmonary Disease","author":"A H Limper","year":"2022","edition":"7 ed."},{"issue":"S 02","key":"ref36","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1038\/sj.bjc.6602063","article-title":"Interstitial lung disease associated with drug therapy","volume":"91","author":"P Camus","year":"2004","journal-title":"Br J Cancer"},{"issue":"04","key":"ref37","doi-asserted-by":"crossref","first-page":"100553","DOI":"10.1016\/j.esmoop.2022.100553","article-title":"Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer","volume":"7","author":"H S Rugo","year":"2022","journal-title":"ESMO Open"},{"issue":"02","key":"ref38","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.ccm.2016.12.004","article-title":"Radiation pneumonitis","volume":"38","author":"T J Bledsoe","year":"2017","journal-title":"Clin Chest Med"},{"issue":"20","key":"ref39","doi-asserted-by":"crossref","first-page":"10969","DOI":"10.3390\/ijms252010969","article-title":"Proton radiation therapy: a systematic review of treatment-related side effects and toxicities","volume":"25","author":"P P Salem","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"05","key":"ref40","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/j.ijrobp.2016.03.024","article-title":"Simple factors associated with radiation-induced lung toxicity after stereotactic body radiation therapy of the thorax: a pooled analysis of 88 studies","volume":"95","author":"J Zhao","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"01","key":"ref41","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2214\/AJR.21.25454","article-title":"Imaging of oncologic treatment-related pneumonitis: a focused review on emerging issues of immune checkpoint inhibitor pneumonitis, from the AJR special series on inflammation","volume":"218","author":"M Nishino","year":"2022","journal-title":"AJR Am J Roentgenol"},{"issue":"05","key":"ref42","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1097\/CMR.0000000000000078","article-title":"Radiation recall dermatitis and radiation pneumonitis during treatment with vemurafenib","volume":"24","author":"A Forschner","year":"2014","journal-title":"Melanoma Res"},{"issue":"04","key":"ref43","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1093\/annonc\/mdv623","article-title":"Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper","volume":"27","author":"S Champiat","year":"2016","journal-title":"Ann Oncol"},{"issue":"01","key":"ref44","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0272-5231(03)00123-0","article-title":"Chemotherapy-induced lung disease","volume":"25","author":"A H Limper","year":"2004","journal-title":"Clin Chest Med"},{"issue":"12","key":"ref45","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"J Haanen","year":"2022","journal-title":"Ann Oncol"},{"issue":"01","key":"ref46","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1186\/s12967-020-02650-z","article-title":"Cellular analysis of bronchoalveolar lavage fluid to narrow differential diagnosis of checkpoint inhibitor-related pneumonitis in metastatic melanoma","volume":"18","author":"S Strippoli","year":"2020","journal-title":"J Transl Med"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"698832","DOI":"10.3389\/fonc.2021.698832","article-title":"Peripheral blood biomarkers for early diagnosis, severity, and prognosis of checkpoint inhibitor-related pneumonitis in patients with lung cancer","volume":"11","author":"X Lin","year":"2021","journal-title":"Front Oncol"},{"issue":"04","key":"ref48","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s10637-017-0524-2","article-title":"Radiomics to predict immunotherapy-induced pneumonitis: proof of concept","volume":"36","author":"R R Colen","year":"2018","journal-title":"Invest New Drugs"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"870842","DOI":"10.3389\/fimmu.2022.870842","article-title":"Development and validation of a radiomics nomogram using computed tomography for differentiating immune checkpoint inhibitor-related pneumonitis from radiation pneumonitis for patients with non-small cell lung cancer","volume":"13","author":"Q Qiu","year":"2022","journal-title":"Front Immunol"},{"issue":"10","key":"ref50","doi-asserted-by":"crossref","first-page":"103715","DOI":"10.1016\/j.esmoop.2024.103715","article-title":"Detection of antibody-drug conjugate-induced interstitial lung disease using circulating cell-free DNA","volume":"9","author":"A Grinshpun","year":"2024","journal-title":"ESMO Open"},{"issue":"09","key":"ref54","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1054\/bjoc.2001.2071","article-title":"Life-threatening hypersensitivity pneumonitis induced by docetaxel (taxotere)","volume":"85","author":"G S Wang","year":"2001","journal-title":"Br J Cancer"},{"issue":"04","key":"ref55","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1378\/chest.129.4.1031","article-title":"A randomized trial of different docetaxel schedules in non-small cell lung cancer patients who failed previous platinum-based chemotherapy","volume":"129","author":"Y M Chen","year":"2006","journal-title":"Chest"},{"issue":"18","key":"ref56","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1016\/S0959-8049(00)00341-5","article-title":"Gemcitabine and paclitaxel associated pneumonitis in non-small cell lung cancer: report of a phase I\/II dose-escalating study","volume":"36","author":"A L Thomas","year":"2000","journal-title":"Eur J Cancer"},{"issue":"10","key":"ref57","doi-asserted-by":"crossref","first-page":"3426","DOI":"10.1200\/JCO.1998.16.10.3426","article-title":"Capillary protein leak syndrome appears to explain fluid retention in cancer patients who receive docetaxel treatment","volume":"16","author":"K A Semb","year":"1998","journal-title":"J Clin Oncol"},{"issue":"09","key":"ref58","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1007\/s12094-007-0106-4","article-title":"Docetaxel-induced interstitial pneumonitis following non-small-cell lung cancer treatment","volume":"9","author":"C Grande","year":"2007","journal-title":"Clin Transl Oncol"},{"issue":"02","key":"ref59","doi-asserted-by":"crossref","first-page":"158","DOI":"10.4103\/lungindia.lungindia_126_21","article-title":"Taxane-induced acute interstitial pneumonitis in patients with breast cancer and outcome of taxane rechallenge","volume":"39","author":"T M Anoop","year":"2022","journal-title":"Lung India"},{"issue":"10","key":"ref60","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1200\/JOP.19.00180","article-title":"Etanercept for treatment of taxane-induced pneumonitis","volume":"15","author":"A K Singavi","year":"2019","journal-title":"J Oncol Pract"},{"issue":"10","key":"ref61","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1007\/s00432-011-1013-1","article-title":"Interstitial lung disease associated with gemcitabine treatment in patients with non-small-cell lung cancer and pancreatic cancer","volume":"137","author":"S Umemura","year":"2011","journal-title":"J Cancer Res Clin Oncol"},{"issue":"07","key":"ref62","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1097\/JTO.0b013e3181a97e17","article-title":"High frequency of radiation pneumonitis in patients with locally advanced non-small cell lung cancer treated with concurrent radiotherapy and gemcitabine after induction with gemcitabine and carboplatin","volume":"4","author":"O Arrieta","year":"2009","journal-title":"J Thorac Oncol"},{"issue":"09","key":"ref63","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1002\/cncr.21808","article-title":"Clinical features and correlates of gemcitabine-associated lung injury: findings from the RADAR project","volume":"106","author":"S M Belknap","year":"2006","journal-title":"Cancer"},{"issue":"13","key":"ref64","doi-asserted-by":"crossref","first-page":"4206","DOI":"10.1158\/1078-0432.CCR-07-5143","article-title":"Efficacy and safety of two doses of pemetrexed supplemented with folic acid and vitamin B12 in previously treated patients with non-small cell lung cancer","volume":"14","author":"Y Ohe","year":"2008","journal-title":"Clin Cancer Res"},{"volume-title":"Pemfexy (pemetrexed) package insert","year":"2020","author":"Eagle Pharmaceuticals","key":"ref65"},{"issue":"01","key":"ref66","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1159\/000336131","article-title":"Interstitial pneumonitis after treatment with pemetrexed: a rare event?","volume":"58","author":"A Hochstrasser","year":"2012","journal-title":"Chemotherapy"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/0169-5002(94)00410-O","article-title":"Fatal pulmonary toxicity following oral etoposide therapy","volume":"12","author":"E Dajczman","year":"1995","journal-title":"Lung Cancer"},{"issue":"02","key":"ref68","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0169-5002(99)00081-1","article-title":"Etoposide-induced pulmonary toxicity","volume":"26","author":"A Gurjal","year":"1999","journal-title":"Lung Cancer"},{"issue":"18","key":"ref69","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa2027071","article-title":"Osimertinib in resected EGFR-mutated non-small-cell lung cancer","volume":"383","author":"Y L Wu","year":"2020","journal-title":"N Engl J Med"},{"issue":"16","key":"ref70","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1056\/NEJMoa2403614","article-title":"Amivantamab plus lazertinib in previously untreated EGFR-mutated advanced NSCLC","volume":"391","author":"B C Cho","year":"2024","journal-title":"N Engl J Med"},{"volume-title":"Lazcluze (lazertinib) package insert","year":"2024","author":"Janssen Biotech","key":"ref72"},{"issue":"04","key":"ref73","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1634\/theoncologist.8-4-303","article-title":"FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets","volume":"8","author":"M H Cohen","year":"2003","journal-title":"Oncologist"},{"issue":"10","key":"ref74","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1097\/JTO.0b013e3181f1c7b0","article-title":"Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV tarceva lung cancer survival treatment study","volume":"5","author":"M Reck","year":"2010","journal-title":"J Thorac Oncol"},{"volume-title":"Vizimpro (dacomitinib) package insert","year":"2018","author":"Pfizer Labs","key":"ref75"},{"issue":"27","key":"ref76","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1200\/JCO.2012.44.2806","article-title":"Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations","volume":"31","author":"L V Sequist","year":"2013","journal-title":"J Clin Oncol"},{"volume-title":"Rybrevant (amivantamab) package insert","year":"2021","author":"Janssen Biotech","key":"ref77"},{"issue":"05","key":"ref78","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1007\/s00280-011-1737-2","article-title":"Drug-induced interstitial lung disease in tyrosine kinase inhibitor therapy for non-small cell lung cancer: a review on current insight","volume":"68","author":"J H Min","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"issue":"03","key":"ref79","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s11523-024-01048-x","article-title":"Real-world data on subsequent therapy for first-line osimertinib-induced pneumonitis: safety of EGFR-TKI rechallenge (Osi-risk study TORG-TG2101)","volume":"19","author":"N Nishioka","year":"2024","journal-title":"Target Oncol"},{"issue":"01","key":"ref80","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s00408-023-00669-9","article-title":"Efficacy and safety of re-administration of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) after EGFR-TKI-induced interstitial lung disease (CS-lung-005)","volume":"202","author":"N Kanaji","year":"2024","journal-title":"Lung"},{"issue":"06","key":"ref81","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1177\/03008916211047888","article-title":"Transient asymptomatic pulmonary opacities and interstitial lung disease in EGFR-mutated non-small cell lung cancer treated with osimertinib","volume":"108","author":"G Taronna","year":"2022","journal-title":"Tumori"},{"issue":"12","key":"ref82","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/S1470-2045(16)30392-8","article-title":"Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1\/2 trial","volume":"17","author":"S N Gettinger","year":"2016","journal-title":"Lancet Oncol"},{"issue":"13","key":"ref83","doi-asserted-by":"crossref","first-page":"13873","DOI":"10.1002\/cam4.5913","article-title":"Incidence of pneumonitis following the use of different anaplastic lymphoma kinase tyrosine kinase inhibitor regimens: an updated systematic review and meta-analysis","volume":"12","author":"W Qie","year":"2023","journal-title":"Cancer Med"},{"issue":"08","key":"ref84","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1097\/JTO.0000000000000577","article-title":"Crizotinib associated with ground-glass opacity predominant pattern interstitial lung disease: a retrospective observational cohort study with a systematic literature review","volume":"10","author":"P Cr\u00e9quit","year":"2015","journal-title":"J Thorac Oncol"},{"issue":"48","key":"ref85","doi-asserted-by":"crossref","first-page":"e18131","DOI":"10.1097\/MD.0000000000018131","article-title":"Anaplastic lymphoma kinase inhibitor related pneumonitis in patients with non-small cell lung cancer: clinical and radiologic characteristics and risk factors","volume":"98","author":"H J Hwang","year":"2019","journal-title":"Medicine (Baltimore)"},{"issue":"34","key":"ref86","doi-asserted-by":"crossref","first-page":"57379","DOI":"10.18632\/oncotarget.18283","article-title":"Meta-analysis of the incidence and risks of interstitial lung disease and QTc prolongation in non-small-cell lung cancer patients treated with ALK inhibitors","volume":"8","author":"L Lin","year":"2017","journal-title":"Oncotarget"},{"volume-title":"Alunbrig (brigatinib) package insert","year":"2020","author":"Takeda Pharmaceutical Company Limitied","key":"ref87"},{"issue":"05","key":"ref88","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1177\/1078155220961557","article-title":"Successful rechallenge of alectinib after remission of severe alectinib-induced interstitial lung disease","volume":"27","author":"J R Huang","year":"2021","journal-title":"J Oncol Pharm Pract"},{"issue":"11","key":"ref89","doi-asserted-by":"crossref","first-page":"e247","DOI":"10.1016\/j.jtho.2019.06.013","article-title":"Early onset pulmonary toxicity with lorlatinib in a patient with previous pulmonary toxicity from brigatinib","volume":"14","author":"X Monzon\u00eds","year":"2019","journal-title":"J Thorac Oncol"},{"issue":"01","key":"ref90","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/s41698-024-00552-7","article-title":"BRAFV600E-mutant metastatic NSCLC: disease overview and treatment landscape","volume":"8","author":"D Planchard","year":"2024","journal-title":"NPJ Precis Oncol"},{"issue":"07","key":"ref91","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1634\/theoncologist.2018-0296","article-title":"Adverse event management in patients with BRAF V600E-mutant non-small cell lung cancer treated with dabrafenib plus trametinib","volume":"24","author":"A Chalmers","year":"2019","journal-title":"Oncologist"},{"issue":"11","key":"ref92","first-page":"685","article-title":"Vemurafenib-induced pulmonary injury","volume":"36","author":"L Schmitt","year":"2013","journal-title":"Onkologie"},{"issue":"08","key":"ref93","doi-asserted-by":"crossref","first-page":"5379","DOI":"10.21037\/jtd-23-629","article-title":"Efficacy and tolerability of osimertinib with dabrafenib and trametinib in BRAF V600E acquired EGFR-mutant non-small cell lung cancer: a case series","volume":"16","author":"K Lu","year":"2024","journal-title":"J Thorac Dis"},{"issue":"02","key":"ref94","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa2204619","article-title":"Adagrasib in non-small-cell lung cancer harboring a KRASG12C mutation","volume":"387","author":"P A J\u00e4nne","year":"2022","journal-title":"N Engl J Med"},{"issue":"25","key":"ref95","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","article-title":"Sotorasib for lung cancers with KRAS p.G12C mutation","volume":"384","author":"F Skoulidis","year":"2021","journal-title":"N Engl J Med"},{"issue":"08","key":"ref96","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1158\/1078-0432.CCR-21-3074","article-title":"FDA approval summary: sotorasib for KRAS G12C-mutated metastatic NSCLC","volume":"28","author":"E C Nakajima","year":"2022","journal-title":"Clin Cancer Res"},{"volume-title":"Krazati (adagrasib) package insert","year":"2024","author":"Mirati Theruapeutics","key":"ref97"},{"issue":"02","key":"ref98","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1158\/1078-0432.CCR-21-1566","article-title":"FDA approval summary: capmatinib and tepotinib for the treatment of metastatic NSCLC harboring MET exon 14 skipping mutations or alterations","volume":"28","author":"L N Mathieu","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"10","key":"ref99","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa2002787","article-title":"Capmatinib in MET exon 14-mutated or MET-amplified non-small-cell lung cancer","volume":"383","author":"J Wolf","year":"2020","journal-title":"N Engl J Med"},{"issue":"02","key":"ref100","first-page":"100271","article-title":"Successful tepotinib challenge after capmatinib-induced interstitial lung disease in a patient with lung adenocarcinoma harboring MET exon 14 skipping mutation: case report","volume":"3","author":"M H Hashiguchi","year":"2021","journal-title":"JTO Clin Res Rep"},{"issue":"20","key":"ref101","doi-asserted-by":"crossref","first-page":"5452","DOI":"10.1158\/1078-0432.CCR-21-0967","article-title":"FDA approval summary: pralsetinib for the treatment of lung and thyroid cancers with RET gene mutations or fusions","volume":"27","author":"J Kim","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"01","key":"ref103","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41698-022-00338-9","article-title":"Antibody-drug conjugates in lung cancer: dawn of a new era?","volume":"7","author":"N Coleman","year":"2023","journal-title":"NPJ Precis Oncol"},{"issue":"03","key":"ref104","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1200\/JCO-24-01544","article-title":"Datopotamab deruxtecan versus docetaxel for previously treated advanced or metastatic non-small cell lung cancer: the randomized, open-label phase III tropion-lung01 study","volume":"43","author":"M J Ahn","year":"2025","journal-title":"J Clin Oncol"},{"issue":"25","key":"ref105","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.1200\/JCO.24.00720","article-title":"Telisotuzumab vedotin monotherapy in patients with previously treated c-met protein-overexpressing advanced nonsquamous EGFR-wildtype non-small cell lung cancer in the phase II luminosity trial","volume":"42","author":"D R Camidge","year":"2024","journal-title":"J Clin Oncol"},{"issue":"07","key":"ref106","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa1914510","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive breast cancer","volume":"382","author":"S Modi","year":"2020","journal-title":"N Engl J Med"},{"issue":"03","key":"ref107","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa2112431","article-title":"Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer","volume":"386","author":"B T Li","year":"2022","journal-title":"N Engl J Med"},{"issue":"31","key":"ref108","doi-asserted-by":"crossref","first-page":"4852","DOI":"10.1200\/JCO.23.01361","article-title":"Trastuzumab deruxtecan in patients with her2-mutant metastatic non-small-cell lung cancer: primary results from the randomized, phase II DESTINY-lung02 trial","volume":"41","author":"K Goto","year":"2023","journal-title":"J Clin Oncol"},{"issue":"08","key":"ref109","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1093\/oncolo\/oyae151","article-title":"FDA approval summary: fam-trastuzumab deruxtecan-nxki for unresectable or metastatic non-small cell lung cancer with activating HER2 mutations","volume":"29","author":"G U Mehta","year":"2024","journal-title":"Oncologist"},{"volume-title":"Kadcyla (trastuzumab emtansine) package insert","year":"2022","author":"Genentech","key":"ref110"},{"key":"ref111","doi-asserted-by":"crossref","first-page":"e2300391","DOI":"10.1200\/PO.23.00391","article-title":"Trastuzumab deruxtecan-related interstitial lung disease\/pneumonitis: computed tomography imaging patterns to guide diagnosis and management","volume":"7","author":"M Nishino","year":"2023","journal-title":"JCO Precis Oncol"},{"issue":"12","key":"ref112","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1007\/s10147-023-02414-x","article-title":"Clinical and imaging features of interstitial lung disease in cancer patients treated with trastuzumab deruxtecan","volume":"28","author":"T Baba","year":"2023","journal-title":"Int J Clin Oncol"},{"issue":"153","key":"ref113","doi-asserted-by":"crossref","first-page":"190058","DOI":"10.1183\/16000617.0058-2019","article-title":"Pulmonary complications of immune checkpoint inhibitors in patients with nonsmall cell lung cancer","volume":"28","author":"J Cadranel","year":"2019","journal-title":"Eur Respir Rev"},{"issue":"06","key":"ref114","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s11912-020-00920-z","article-title":"Checkpoint inhibitor pneumonitis: mechanisms, characteristics, management strategies, and beyond","volume":"22","author":"J E Reuss","year":"2020","journal-title":"Curr Oncol Rep"},{"issue":"07","key":"ref115","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1200\/JCO.2016.68.2005","article-title":"Pneumonitis in patients treated with anti-programmed death-1\/programmed death ligand 1 therapy","volume":"35","author":"J Naidoo","year":"2017","journal-title":"J Clin Oncol"},{"key":"ref116","doi-asserted-by":"crossref","first-page":"663986","DOI":"10.3389\/fimmu.2021.663986","article-title":"Immune checkpoint inhibitor-associated pneumonitis in non-small cell lung cancer: current understanding in characteristics, diagnosis, and management","volume":"12","author":"Q Zhang","year":"2021","journal-title":"Front Immunol"},{"issue":"25","key":"ref117","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1200\/JCO.2016.66.9861","article-title":"Nivolumab in combination with platinum-based doublet chemotherapy for first-line treatment of advanced non-small-cell lung cancer","volume":"34","author":"N A Rizvi","year":"2016","journal-title":"J Clin Oncol"},{"issue":"10","key":"ref118","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1001\/jamaoncol.2016.1051","article-title":"Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review","volume":"2","author":"C F Friedman","year":"2016","journal-title":"JAMA Oncol"},{"issue":"36","key":"ref119","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"B J Schneider","year":"2021","journal-title":"J Clin Oncol"},{"issue":"01","key":"ref120","doi-asserted-by":"crossref","first-page":"e007409","DOI":"10.1136\/jitc-2023-007409","article-title":"Corticosteroid-resistant immune-related adverse events: a systematic review","volume":"12","author":"E Daetwyler","year":"2024","journal-title":"J Immunother Cancer"},{"issue":"02","key":"ref121","doi-asserted-by":"crossref","first-page":"e001884","DOI":"10.1136\/jitc-2020-001884","article-title":"Success and failure of additional immune modulators in steroid-refractory\/resistant pneumonitis related to immune checkpoint blockade","volume":"9","author":"J Beattie","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"10","key":"ref122","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1016\/j.jtho.2021.06.024","article-title":"Beyond steroids: immunosuppressants in steroid-refractory or resistant immune-related adverse events","volume":"16","author":"J Luo","year":"2021","journal-title":"J Thorac Oncol"},{"issue":"01","key":"ref123","doi-asserted-by":"crossref","first-page":"e001731","DOI":"10.1136\/jitc-2020-001731","article-title":"Steroid-refractory PD-(L)1 pneumonitis: incidence, clinical features, treatment, and outcomes","volume":"9","author":"A Balaji","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"11","key":"ref124","doi-asserted-by":"crossref","first-page":"e1575","DOI":"10.1093\/oncolo\/oyae147","article-title":"Investigating risk factors and treatment options for severe, partially steroid responsive, and steroid-refractory checkpoint inhibitor pneumonitis","volume":"29","author":"M Moodabagil","year":"2024","journal-title":"Oncologist"},{"issue":"03","key":"ref125","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1177\/1078155217745144","article-title":"Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade","volume":"25","author":"C R Stroud","year":"2019","journal-title":"J Oncol Pharm Pract"},{"key":"ref126","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1016\/S0140-6736(16)00232-4","article-title":"Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial","volume":"387","author":"D Khanna","year":"2016","journal-title":"Lancet"},{"key":"ref127","first-page":"100969","article-title":"Prevalence and outcome of steroid-resistant\/refractory pneumonitis induced by immune checkpoint inhibitors","volume":"82","author":"M Camard","year":"2022","journal-title":"Respir Med Res"},{"key":"ref128","doi-asserted-by":"crossref","first-page":"1072612","DOI":"10.3389\/fimmu.2022.1072612","article-title":"Nintedanib in an elderly non-small-cell lung cancer patient with severe steroid-refractory checkpoint inhibitor-related pneumonitis: a case report and literature review","volume":"13","author":"L Pan","year":"2023","journal-title":"Front Immunol"},{"issue":"11","key":"ref129","doi-asserted-by":"crossref","first-page":"3765","DOI":"10.1007\/s00262-023-03528-x","article-title":"Second-line immunosuppressant administration for steroid-refractory immune-related adverse events in patients with lung cancer","volume":"72","author":"S Ogusu","year":"2023","journal-title":"Cancer Immunol Immunother"},{"issue":"06","key":"ref130","doi-asserted-by":"crossref","first-page":"e006982","DOI":"10.1136\/jitc-2023-006982","article-title":"Risk factors and immunomodulators use in steroid-refractory checkpoint inhibitor pneumonitis","volume":"11","author":"Y Li","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"10","key":"ref131","doi-asserted-by":"crossref","first-page":"4305","DOI":"10.1172\/JCI128654","article-title":"The alveolar immune cell landscape is dysregulated in checkpoint inhibitor pneumonitis","volume":"129","author":"K Suresh","year":"2019","journal-title":"J Clin Invest"}],"container-title":["Seminars in Respiratory and Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2666-7519.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T23:37:00Z","timestamp":1767656220000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2666-7519"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,28]]},"references-count":125,"journal-issue":{"issue":"05","published-online":{"date-parts":[[2026,1,5]]},"published-print":{"date-parts":[[2025,10]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2666-7519","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["1069-3424","1098-9048"],"issn-type":[{"type":"print","value":"1069-3424"},{"type":"electronic","value":"1098-9048"}],"subject":[],"published-other":{"date-parts":[[2025,7,28]]},"published":{"date-parts":[[2025,7,28]]}}}